Download PDF
CC BY-NC-ND 4.0 · Journal of Gastrointestinal and Abdominal Radiology 2019; 02(02): 107-115
DOI: 10.1055/s-0039-1692016
Review Article
Indian Society of Gastrointestinal and Abdominal Radiology

Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 2

Akshay D. Baheti
1   Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Ashita Rastogi 
2   Department of Radiodiagnosis, Delhi State Cancer Institute, New Delhi, India
,
Aravintho Natarajan
3   Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Anurima Patra
1   Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Sree Harsha Tirumani
4   Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
5   Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
› Author Affiliations
Further Information

Publication History

Received: 03 March 2019

Accepted after revision: 26 March 2019

Publication Date:
06 August 2019 (online)

   Permissions and Reprints

Abstract

The rapid recent advances in oncology have made the dream of precision oncology a reality, with targeted therapy available for various tumors depending on the molecular genotype. This has led to the corresponding development of personalized radiology as well, with various tumor response criteria used to characterize disease response/progression depending on chemotherapy used. In these two review articles, we review the various tumor response criteria widely applied in both research and clinical settings. These include the classic size-based criteria such as RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 and the WHO (World Health Organization) criteria, as also various other criteria such as Choi and modified Choi criteria for tumors treated by targeted therapy, EASL (European Association for the Study of the Liver) and modified RECIST (mRECIST) criteria for hepatocellular carcinomas, immune-related response criteria (irRC) and immune RECIST (iRECIST) for patients on immunotherapy. Other clinically important criteria such as PERCIST (PET Response Criteria In Solid Tumors) for positron emission tomography–computed tomography (PET-CT), and the MD Anderson criteria for evaluating bone metastases are also highlighted.

Keywords

treatment response - modified RECIST - Choi criteria - MD Anderson criteria - PERCIST - immune RECIST
 

  • References

  • 1 Tirumani SH, Baheti AD, Tirumani H, O'Neill A, Jagannathan JP. Update on gastrointestinal stromal tumors for radiologists. Korean J Radiol 2017; 18 (01) 84-93
    CrossrefPubMedGoogle Scholar
  • 2 Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, Ramaiya NH. Imatinib and beyond in gastrointestinal stromal tumors: a radiologist's perspective. Am J Roentgenol 2013; 201 (04) 801-810
    CrossrefPubMedGoogle Scholar
  • 3 Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13 (Suppl. 02) 4-7
    PubMedGoogle Scholar
  • 4 Gonzalez-Guindalini FD, Botelho MPF, Harmath CB. et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 2013; 33 (06) 1781-1800
    CrossrefPubMedGoogle Scholar
  • 5 Nishino M, Tirumani SH, Ramaiya NHHF, Hodi FS. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol 2015; 84 (07) 1259-1268
    CrossrefPubMedGoogle Scholar
  • 6 Choi Y, Kim DH, Jin SY, Lee AY, Lee SH. Topical immunotherapy with diphenylcyclopropenone is effective and preferred in the treatment of periungual warts. Ann Dermatol 2013; 25 (04) 434-439
    CrossrefPubMedGoogle Scholar
  • 7 O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. Am J Roentgenol 2011; 197 (02) W241-6
    CrossrefPubMedGoogle Scholar
  • 8 Wolchok JD, Hoos A, O'Day S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15 (23) 7412-7420
    CrossrefPubMedGoogle Scholar
  • 9 Nishino M, Jagannathan JP, Krajewski KM. et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. Am J Roentgenol 2012; 198 (04) 737-745
    CrossrefPubMedGoogle Scholar
  • 10 Seymour L, Bogaerts J, Perrone A. et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18 (03) e143-e152
    CrossrefPubMedGoogle Scholar
  • 11 Llovet JM, Ducreux M, Lencioni R. et al; European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
    CrossrefPubMedGoogle Scholar
  • 12 Subbiah V, Chuang HH, Gambhire D, Kairemo K. Defining clinical response criteria and early response criteria for precision oncology: current state-of-the-art and future perspectives. Diagnostics (Basel) 2017; 7 (01) 10
    CrossrefPubMedGoogle Scholar
  • 13 Arslanoglu A, Seyal AR, Sodagari F. et al Current guidelines for the diagnosis and management of hepatocellular carcinoma: a comparative review. Am J Roentgenol 2016; 207 (05) W88-W98
    CrossrefPubMedGoogle Scholar
  • 14 Bruix J, Sherman M, Llovet JM. et al; EASL Panel of Experts on HCC; European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35 (03) 421-430
    CrossrefPubMedGoogle Scholar
  • 15 Llovet JM, Di Bisceglie AM, Bruix J. et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (10) 698-711
    CrossrefPubMedGoogle Scholar
  • 16 Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res 2013; 19 (06) 1312-1314
    CrossrefPubMedGoogle Scholar
  • 17 Woolf DK, Padhani AR, Makris A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?. Ann Oncol 2015; 26 (06) 1048-1057
    CrossrefPubMedGoogle Scholar
  • 18 Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 2010; 1 (01) 80-92
    Google Scholar
  • 19 Schwartz LH, Seymour L, Litière S. et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer 2016; 62 (March): 138-145
    CrossrefPubMedGoogle Scholar
  • 20 WHO Handbook for Reporting Results of Cancer Treatment. Vol. 48, World Health Organization Offset Publication; 1979
    Google Scholar
  • 21 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedGoogle Scholar
  • 22 Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22 (14) 2942-2953
    CrossrefPubMedGoogle Scholar
  • 23 Bos R, van Der Hoeven JJ, van Der Wall E. et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20 (02) 379-387
    CrossrefPubMedGoogle Scholar
  • 24 Young H, Baum R, Cremerius U. et al; European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35 (13) 1773-1782
    CrossrefPubMedGoogle Scholar
  • 25 Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (01) (Suppl. 01) 122S-150S
    CrossrefPubMedGoogle Scholar
  • 26 Min SJ, Jang HJ, Kim JH. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review. Oncotarget 2016; 7 (19) 27848-27854
    CrossrefPubMedGoogle Scholar
  • 27 Shang J, Ling X, Zhang L. et al. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2016; 43 (11) 1945-1953
    CrossrefPubMedGoogle Scholar
  • 28 Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 3 (05) 637-640
    CrossrefPubMedGoogle Scholar
  • 29 Juweid ME, Stroobants S, Hoekstra OS. et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25 (05) 571-578
    CrossrefPubMedGoogle Scholar
  • 30 Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50 (08) 1257-1260
    CrossrefPubMedGoogle Scholar
  • 31 Cheson BD, Fisher RI, Barrington SF. et al; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27) 3059-3068
    CrossrefPubMedGoogle Scholar
  • 32 Chang SM, Wen PY, Vogelbaum MA, Macdonald DR, van den Bent MJ. Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma: . Neurooncol Pract 2015; 2 (04) 205-209
    PubMed
  • 33 Smith1 AD. Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am J Roentgenol 2010; 194 (06) 1470-1478
    CrossrefPubMedGoogle Scholar
  • 34 Krajewski KM, Guo M, Van den Abbeele AD. et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011; 59 (05) 856-862
    CrossrefPubMedGoogle Scholar
  • 35 Arya S, Das D, Engineer R, Saklani A. Imaging in rectal cancer with emphasis on local staging with MRI. Indian J Radiol Imaging 2015; 25 (02) 148-161
    Article in Thieme ConnectPubMedGoogle Scholar